Skip to main content

Table 3 Multivariate Cox regression analysis for patient survival

From: MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

Entire cohort (N = 119)

N of patients

N of events

Hazard ratio

95 % CI

Wald’s p

 Performance status

  1–2–3 vs. 0

32 vs. 87

27 vs. 61

1.64

1.03–2.62

0.036

 TOP2A (FISH) ratio 2.0 copies 4.0

  Amplified vs. non-amplified

42 vs. 77

28 vs. 60

0.62

0.38–1.00

0.050

 MYC CN

  Gain vs. no gain

10 vs. 109

10 vs. 78

6.02

2.67–13.6

<0.001

 Type of disease*CEN profile (binary)

    

0.048

  CEN profile, 1chr vs. other @ R-mBC

28 vs. 58

24 vs. 39

2.29

1.36–3.85

 

  CEN profile, 1chr vs. other @ de novo-mBC

12 vs. 21

9 vs. 16

0.77

0.29–2.04

 

  de novo-mBC vs. R-mBC @ CEN profile, other

21 vs. 58

16 vs. 39

1.15

0.64–2.08

 

  de novo-mBC vs. R-mBC @ CEN profile, 1chr

12 vs. 28

9 vs. 24

0.39

0.16–0.93

 

HER2-positive (N = 83)

 TOP2A (FISH) ratio 2.0 copies 4.0

  Amplified vs. non-amplified

39 vs. 44

25 vs. 35

0.58

0.35–0.98

0.041

 MYC CN

  Gain vs. no gain

7 vs. 76

7 vs. 53

4.40

1.90–10.2

0.001

HER2-negative (N = 45)

 Menopausal status

  Post vs. pre

28 vs. 17

25 vs. 10

3.69

1.57–8.65

0.003

 ER/PgR

  Positive vs. negative

39 vs. 6

29 vs. 6

0.22

0.08–0.58

0.002

 MYC FISH binary (ratio 2, copies >5)

  Amplified vs. non-amplified

4 vs. 41

4 vs. 31

4.54

1.40–14.70

0.012

 Ki67 (by increase 5 %)

  

1.16

1.07–1.26

0.001

R-mBC (N = 84)

 Age

  ≥50 vs. <50

56 vs. 28

39 vs. 23

0.50

0.28–0.89

0.019

 Performance status

  1-2-3 vs. 0

25 vs. 59

22 vs. 40

1.83

1.07–3.14

0.028

 ER/PgR

  Positive vs. negative

57 vs. 27

39 vs. 23

0.43

0.24–0.76

0.004

 PI3K

  Activation vs. non-activation

74 vs. 10

56 vs. 6

4.50

1.63–12.39

0.004

 MYC CN

  Gain vs. no gain

6 vs. 78

6 vs. 56

20.48

6.77–61.99

<0.001

de novo-mBC (N = 49)

 Performance status

  1-2-3 vs. 0

13 vs. 36

12 vs. 26

1.99

0.99–4.02

0.055

 ER/PgR

  Positive vs. negative

36 vs. 13

27 vs. 11

0.16

0.03–0.77

0.023

 HER2 status/subtypes

    

0.13

  Luminal HER2 vs. HER2-negative

21 vs. 17

16 vs. 13

1.15

0.53–2.49

0.72

  HER-enriched vs. HER2-negative

11 vs. 17

9 vs. 13

0.20

0.04–0.96

0.045

  1. N number, CI confidence interval, CN copy number, italics unfavorable, bold italics favorable prediction
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us